Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2024; 19(03): 412-418
DOI: 10.1055/s-0044-1787674
Original Article

Physical Health-Related Quality of Life and Postsurgical Outcomes in Brain Tumor Resection Patients

Renuka Chintapalli 
1   School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Hills Road, Cambridge, United Kingdom
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Patient-reported outcome measures (PROMs) have gained traction in assessing patients' health around surgery. Among these, the 29-item Patient-Reported Outcomes Measurement Information System (PROMIS-29) is a widely accepted tool for evaluating overall health, yet its applicability in cranial neurosurgery remains uncertain.

Objective This study aimed to evaluate the predictive value of preoperative PROMIS-29 scores for postoperative outcomes in patients undergoing brain tumor resection.

Materials and Methods We identified adult patients undergoing brain tumor resection at a single neurosurgical center between January 2018 and December 2021. We analyzed physical health (PH) summary scores to determine optimal thresholds for predicting length of stay (LOS), discharge disposition (DD), and 30-day readmission. Bivariate analyses were conducted to examine the distribution of PH scores based on patient characteristics. Multivariate logistic regression models were employed to assess the association between preoperative PH scores and short-term postoperative outcomes.

Results Among 157 patients (mean age 55.4 years, 58.0% female), 14.6% exhibited low PH summary scores. Additionally, 5.7% experienced prolonged LOS, 37.6% had nonroutine DDs, and 19.1% were readmitted within 30 days. Bivariate analyses indicated that patients with low PH summary scores, indicating poorer baseline PH, were more likely to have malignant tumors, nonelective admissions, and adverse outcomes. In multivariate analysis, low PH summary scores independently predicted increased odds of prolonged LOS (odds ratio [OR] = 6.09, p = 0.003), nonroutine DD (OR = 4.25, p = 0.020), and 30-day readmission (OR = 3.93, p = 0.020).

Conclusion The PROMIS-29 PH summary score serves as a valuable predictor of short-term postoperative outcomes in brain tumor patients. Integrating this score into clinical practice can enhance the ability to anticipate meaningful postoperative results.

Keywords

PROMIS-29 - length of stay - discharge disposition - readmission - brain tumors

Ethical Approval

This study has been approved by the appropriate ethics committee and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study. The data can be made available from the author on reasonable request.




Publication History

Article published online:
10 June 2024

© 2024. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Miller KD, Ostrom QT, Kruchko C. et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 2021; 71 (05) 381-406
    CrossrefPubMedGoogle Scholar
  • 2 Liu Z, Han L, Gahbauer EA, Allore HG, Gill TM. Joint trajectories of cognition and frailty and associated burden of patient-reported outcomes. J Am Med Dir Assoc 2018; 19 (04) 304-309.e2
    CrossrefPubMedGoogle Scholar
  • 3 Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro-oncol 2016; 18 (02) 252-260
    CrossrefPubMedGoogle Scholar
  • 4 Heimans JJ, Taphoorn MJB. Impact of brain tumour treatment on quality of life. J Neurol 2002; 249 (08) 955-960
    CrossrefPubMedGoogle Scholar
  • 5 Karnofsky DA. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. M.. Ed. Evaluation of Chemotherapeutic Agents. Columbia University Press; New York: 1949: 196
    Google Scholar
  • 6 Oken MM, Creech RH, Tormey DC. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (06) 649-655
    CrossrefPubMedGoogle Scholar
  • 7 Schaafsma J, Osoba D. The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30. Qual Life Res 1994; 3 (06) 413-424
    CrossrefPubMedGoogle Scholar
  • 8 Bartlett SJ, Orbai AM, Duncan T. et al. Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS One 2015; 10 (09) e0138543
    CrossrefPubMedGoogle Scholar
  • 9 U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79
    CrossrefPubMedGoogle Scholar
  • 10 Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA 2012; 307 (15) 1583-1584
    CrossrefPubMedGoogle Scholar
  • 11 Santana MJ, Haverman L, Absolom K. et al. Training clinicians in how to use patient-reported outcome measures in routine clinical practice. Qual Life Res 2015; 24 (07) 1707-1718
    CrossrefPubMedGoogle Scholar
  • 12 Basch E, Abernethy AP, Mullins CD. et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 2012; 30 (34) 4249-4255
    CrossrefPubMedGoogle Scholar
  • 13 Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 2007; (37) 16-21
    CrossrefPubMedGoogle Scholar
  • 14 Dirven L, Vos ME, Walbert T. et al. Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. Neurooncol Pract 2021; 8 (04) 417-425
    PubMedGoogle Scholar
  • 15 Cella D, Yount S, Rothrock N. et al; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45 (05, suppl 1): S3-S11
    CrossrefPubMedGoogle Scholar
  • 16 Hays RD, Staquet MJ, Fayers PM. Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford, United Kingdom: Oxford University Press; 1998
    Google Scholar
  • 17 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014; 12 (12) 1495-1499
    CrossrefPubMedGoogle Scholar
  • 18 Lingsma HF, Bottle A, Middleton S, Kievit J, Steyerberg EW, Marang-van de Mheen PJ. Evaluation of hospital outcomes: the relation between length-of-stay, readmission, and mortality in a large international administrative database. BMC Health Serv Res 2018; 18 (01) 116
    CrossrefPubMedGoogle Scholar
  • 19 Vîjan AE, Daha IC, Delcea C, Dan GA. Determinants of prolonged length of hospital stay of patients with atrial fibrillation. J Clin Med 2021; 10 (16) 3715
    CrossrefPubMedGoogle Scholar
  • 20 Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS®-29 v2.0 profile physical and mental health summary scores. Qual Life Res 2018; 27 (07) 1885-1891
    CrossrefPubMedGoogle Scholar
  • 21 Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3 (01) 32-35
    CrossrefPubMedGoogle Scholar
  • 22 Lai JS, Kupst MJ, Beaumont JL. et al. Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to measure symptom burden reported by patients with brain tumors. Pediatr Blood Cancer 2019; 66 (03) e27526
    CrossrefPubMedGoogle Scholar
  • 23 Yang L, Xu Z-Y, Zhang H, Kong FM. Assessment of patient-reported outcomes in patients treated with radiation therapy to brain malignant tumors. J Clin Oncol 2020; 38 (15, suppl): e14521-e14521
    CrossrefGoogle Scholar
  • 24 Leu S, Boulay JL, Thommen S. et al. Preoperative two-dimensional size of glioblastoma is associated with patient survival. World Neurosurg 2018; 115: e448-e463
    CrossrefPubMedGoogle Scholar
  • 25 Gibbs D, Ehwerhemuepha L, Moreno T. et al. Prolonged hospital length of stay in pediatric trauma: a model for targeted interventions. Pediatr Res 2021; 90 (02) 464-471
    CrossrefPubMedGoogle Scholar
  • 26 Von Rueden KT, Harris JR. Pulmonary dysfunction related to immobility in the trauma patient. AACN Clin Issues 1995; 6 (02) 212-228
    CrossrefPubMedGoogle Scholar
  • 27 Huq S, Khalafallah AM, Jimenez AE. et al. Predicting postoperative outcomes in brain tumor patients with a 5-Factor Modified Frailty Index. Neurosurgery 2020; 88 (01) 147-154
    CrossrefPubMedGoogle Scholar
  • 28 Chang YW, Chen WL, Lin FG. et al. Frailty and its impact on health-related quality of life: a cross-sectional study on elder community-dwelling preventive health service users. PLoS One 2012; 7 (05) e38079
    CrossrefPubMedGoogle Scholar
  • 29 Bonney PA, Chartrain AG, Briggs RG. et al. Frailty is associated with in-hospital morbidity and nonroutine disposition in brain tumor patients undergoing craniotomy. World Neurosurg 2021; 146: e1045-e1053
    CrossrefPubMedGoogle Scholar
  • 30 Thommen R, Kazim SF, Rumalla K. et al. Preoperative frailty measured by risk analysis index predicts complications and poor discharge outcomes after brain tumor resection in a large multi-center analysis. J Neurooncol 2022; 160 (02) 285-297
    CrossrefPubMedGoogle Scholar
  • 31 Sastry RA, Pertsch NJ, Tang O, Shao B, Toms SA, Weil RJ. Frailty and outcomes after craniotomy for brain tumor. J Clin Neurosci 2020; 81: 95-100
    CrossrefPubMedGoogle Scholar
  • 32 van Walraven C, Wong J, Forster AJ. LACE+ index: extension of a validated index to predict early death or urgent readmission after hospital discharge using administrative data. Open Med 2012; 6 (03) e80-e90
    PubMedGoogle Scholar